LV
LVCLF.US Living Cell Technologies Limited
- Market cap
- USD 14.5M
- P/E
- -
- P/B
- 4.98x
- ROE
- -66.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is LVCLF.US undervalued?
Graham numberThe Graham number of Living Cell Technologies Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Living Cell Technologies Limited fundamental analysis
No fundamental analysis for Living Cell Technologies Limited yet.
Living Cell Technologies Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingr…
Full company profileLiving Cell Technologies Limited financial statements
Living Cell Technologies Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 115K | 121K | 9.77K | 3.17K | 268K | 3.41K | 42.0K | 125K | - | - |
| Gross Profit | 115K | 121K | 9.77K | 3.17K | 219K | 2.66K | 41.5K | 125K | - | - |
| Operating Income | -5.25M | -4.27M | -4.16M | -3.16M | -2.01M | -2.38M | -2.09M | -2.08M | -1.56M | -3.26M |
| EBITDA | -5.18M | -4.21M | -4.11M | -3.09M | -1.29M | -1.46M | -1.52M | -1.58M | -1.11M | -3.26M |
| Net Income | -4.09M | -374K | -3.18M | -968K | -1.46M | -1.96M | -2.11M | -2.10M | -803K | -2.81M |
| EPS | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.69M | 7.61M | 5.76M | 3.39M | 1.64M | 4.27M | 4.21M | 3.19M | 2.40M | 4.43M |
| Total Liabilities | 1.18M | 473K | 1.62M | 513K | 265K | 239K | 450K | 178K | 170K | 176K |
| Shareholders' Equity | 7.52M | 7.14M | 4.14M | 2.88M | 1.38M | 4.03M | 3.76M | 3.01M | 2.23M | 4.26M |
| Cash & Short-term Investments | 7.53M | 6.86M | 4.91M | 2.96M | 1.61M | 4.24M | 4.11M | 3.11M | 2.32M | 3.93M |
| Total Debt | - | - | - | 255K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.37M | -3.57M | -1.99M | -3.11M | -1.46M | -2.04M | -1.99M | -1.52M | -785.00 | -2.70M |
| Capital Expenditure | 249K | 2.99K | 53.3K | 3.80K | 3.80K | 3.80K | 0.00 | 0.00 | 0.00 | 3.00 |
| Free Cash Flow | -3.62M | -3.57M | -2.04M | -3.11M | -1.46M | -2.05M | -1.99M | -1.52M | -785.00 | -2.70M |
| Ratios | ||||||||||
| ROE | -54.4% | -5.2% | -76.9% | -33.6% | -106.1% | -48.5% | -56.0% | -69.5% | -36.0% | -66.0% |
| ROA | -47.0% | -4.9% | -55.2% | -28.6% | -88.9% | -45.8% | -50.0% | -65.6% | -33.5% | -63.4% |
| Net Profit Margin | -3,548.1% | -308.5% | -32,565.9% | -30,570.4% | -544.6% | -57,483.1% | -5,016.3% | -1,673.8% | - | - |
| Debt to Equity | - | - | - | 0.09x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Living Cell Technologies Limited dividends
Living Cell Technologies Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 81:80 on Apr 3, 2023.
Who owns Living Cell Technologies Limited
- Insiders 35.30%
- Institutions 0.00%
- Public & others 64.71%
- Shares outstanding 2.03B
- Free float 1.47B
Living Cell Technologies Limited company profile
- Company name
- Living Cell Technologies Limited
- Ticker
- LVCLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Rialto South Tower, Melbourne, VIC, Australia, 3000
- Phone
- 61 2 9698 5414
- Website
- algoraepharma.com
About Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Living Cell Technologies Limited management
8- Mr. David Richard HainsworthCEO & Executive Chairman · born 1973
- Mr. David GullandCOO & Director
- Mr. Vishal ShahChief Commercial Officer
- Dr. James A. MckennaChief Scientific Officer
- Mr. Waleed ElsayedHead of Sales
- Dr. Carolyn M. Sue A.M., B.S., Ph.D.Member of Medical Advisory Board & Chief Medical Officer of NTCELL · born 1964
- Ms. Catherine EarlieJoint Company Secretary
- Ms. Geraldine HollandJoint Company Secretary